Try our beta test site

Preanalgesic Effect of Gabapentin in Total Knee Repair

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Texas Health Resources
ClinicalTrials.gov Identifier:
NCT00279487
First received: January 16, 2006
Last updated: October 24, 2016
Last verified: October 2016
  Purpose
The purpose of this study is to determine whether gabapentin, as a one time administration prior to a total knee replacement procedure, has opioid sparing effects and a reduction in pain scores.

Condition Intervention
Pain
Drug: Gabapentin
Drug: Placebos

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Preanalgesic Effect of Gabapentin in Total Knee Repair

Resource links provided by NLM:


Further study details as provided by Texas Health Resources:

Enrollment: 24
Study Completion Date: August 2007
Arms Assigned Interventions
Active Comparator: Arm 1
Patients will receive 1200mg gabapentin 1-2 hours prior to surgery.
Drug: Gabapentin
Placebo Comparator: Arm 2
Patients will receive placebo 1-2 hours prior to surgery.
Drug: Placebos

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients undergoing total knee replacement who received pain management by the following modality:

    • Intravenous patient-controlled analgesia (IV-PCA) opioid
    • Local femoral nerve block with 1.5% mepivacaine 20 ml and 0.5% ropivacaine 20 ml

Exclusion Criteria:

  • Age < 18 years old
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00279487

Locations
United States, Texas
Presbyterian Hospital of Dallas
Dallas, Texas, United States, 75231
Sponsors and Collaborators
Texas Health Resources
Investigators
Principal Investigator: Rob Hutchison Texas Health Resources
  More Information

Responsible Party: Texas Health Resources
ClinicalTrials.gov Identifier: NCT00279487     History of Changes
Other Study ID Numbers: P768
Study First Received: January 16, 2006
Last Updated: October 24, 2016
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Texas Health Resources:
Patients undergoing total knee replacement who received pain management by the following modality:
IV PCA opioid
Local femoral nerve block with 1.5% Mepivacaine & 0.5% Ropivacaine

Additional relevant MeSH terms:
Gabapentin
gamma-Aminobutyric Acid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anticonvulsants
Antiparkinson Agents
Anti-Dyskinesia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Antimanic Agents
GABA Agents

ClinicalTrials.gov processed this record on March 24, 2017